公开(公告)号：WO2021127528A1

公开(公告)日：2021-06-24

申请号：PCT/US2020/066157

申请日：2020-12-18

Applicant: AMGEN INC.

Inventor： YU, Xin ,  EGEN, Jackson ,  GARCES, Fernando ,  TAKENAKA, Shunsuke ,  KIM, AeRyon ,  SAWANT, Deepali

IPC: C07K16/28 ,  C07K16/30 ,  A61P35/00 ,  A61K39/00 ,  A61K2039/507 ,  C07K16/2878 ,  C07K16/3076 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/75 ,  C07K2317/92 ,  C07K2319/00

Abstract: The present invention relates to a human agonistic CD40 multispecific antibody construct for treatment of solid tumors by engineering a molecule that specifically targets the CD40 pathway on tumor-associated APCs, without systemic CD40 activation.

公开(公告)号：WO2019140196A1

公开(公告)日：2019-07-18

申请号：PCT/US2019/013205

申请日：2019-01-11

Applicant: AMGEN INC.

Inventor： ALI, Khaled, M.K.Z. ,  AGRAWAL, Neeraj Jagdish ,  KANNAN, Gunasekaran ,  FOLTZ, Ian ,  WANG, Zhulun ,  BATES, Daren ,  MOCK, Marissa ,  TAKENAKA, Shunsuke

IPC: C07K14/54 ,  A61K47/60 ,  A61K47/54 ,  C07K16/28

Abstract: Provided herein are PD-1 antigen-binding proteins and related nucleic acids, vectors, host cells, kits and pharmaceutical compositions. Methods of making PD-1 antigen-binding proteins and methods of treating a subject are further provided.

公开(公告)号：WO2020023268A1

公开(公告)日：2020-01-30

申请号：PCT/US2019/042234

申请日：2019-07-17

Applicant: AMGEN INC.

Inventor： YU, Xin ,  OUYANG, Wenjun ,  LI, Chi-Ming Kevin ,  EGEN, Jackson Graeme ,  YOON, Oh Kyu ,  DRIVER, Ian Halsey ,  TAKENAKA, Shunsuke ,  THOMSON, Christy Ann ,  WANG, Hongyu

IPC: C07K16/28 ,  A61K39/395

Abstract: This invention relates to combination therapies comprising a Programmed Death 1 receptor (PD-1) pathway inhibitor, and a Leukocyte Immunoglobulin Like Receptor B (LILRB) signaling inhibitor, and the use of the combination therapies for the treatment of cancer. The invention also relates to the treatment of cancer patients who are refractory to monotherapy with a PD-1 pathway inhibitor.